ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

HOTH Hoth Therapeutics Inc

1,09
-0,04 (-3,54%)
08 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Hoth Therapeutics Inc HOTH NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
-0,04 -3,54% 1,09 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,12 1,09 1,14 1,09 1,13
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/5/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/5/202414:00PRNUSHoth Therapeutics to Attend EF Hutton Annual Global..
27/3/202419:00PRNUSHoth Therapeutics Announces Exercise of Warrants for $4.2..
27/3/202413:27PRNUSHoth Therapeutics' Wholly Owned Subsidiary Merveille.ai,..
19/3/202413:21PRNUSHoth Therapeutics Announces Positive Data In Completed Study..
29/2/202414:38PRNUSHoth Therapeutics Retains Venable LLP to Expand Its Patent..
26/2/202414:11PRNUSHoth Therapeutics Engages Altasciences to Perform Key Study..
13/2/202417:45PRNUSHoth Therapeutics to Attend BIO CEO and Investor Conference,..
18/1/202414:20PRNUSHoth Therapeutics Announces it Received FDA Approval to..
09/1/202421:03EDGAR2Form 8-K - Current report
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202314:21PRNUSHoth Therapeutics Announces Expansion of FDA Cleared..
05/12/202314:33PRNUSHoth Therapeutics Announces it Has Successfully Completed..
14/11/202314:37PRNUSHoth Therapeutics Announces Successful Completion of Pre-IND..
13/11/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/11/202314:00PRNUSHoth Therapeutics to Present at NobleCon's 19th Annual..
05/10/202316:03PRNUSHoth Therapeutics Announces Merveille.ai Artificial..
05/10/202314:15EDGAR2Form 8-K - Current report
02/10/202314:33PRNUSFDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT,..
15/9/202322:15EDGAR2Form 8-K - Current report
15/9/202320:38PRNUSHoth Therapeutics Announces Closing of $2.89 Million..
14/9/202323:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/9/202319:43PRNUSHoth Therapeutics Announces $2.89 Million Registered Direct..
13/9/202314:16PRNUSHoth Therapeutics Announces Positive Results Killing Cancer..
11/9/202316:04PRNUSHoth Therapeutics Announces FDA Accepts Pre-Investigational..
06/9/202314:12PRNUSHoth Therapeutics Announces Positive Final Results from..
21/8/202323:10EDGAR2Form 8-K - Current report
21/8/202323:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202314:13PRNUSHoth Therapeutics Announces Positive Preclinical End Point..
25/7/202314:12PRNUSHoth Therapeutics Announces Major Milestone of First Patient..
19/7/202314:02PRNUSHoth Therapeutics Receives Protocol Approval for HT-001..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202314:12PRNUSHoth Therapeutics Announces IRB Approval for FDA Cleared..